Cantor Fitzgerald Reiterates Overweight on Orchard Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Orchard Therapeutics (NASDAQ:ORTX) and maintained a $15 price target.
June 27, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Orchard Therapeutics and maintained a $15 price target.
The reiteration of an Overweight rating and maintenance of a $15 price target by Cantor Fitzgerald analyst Pete Stavropoulos indicates a positive outlook for Orchard Therapeutics. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100